Madrigal reports real-world data showing Rezdiffra improves liver health measures through 12 months

PUBT · 2d ago
Madrigal reports real-world data showing Rezdiffra improves liver health measures through 12 months
  • Madrigal Pharmaceuticals will present new Rezdiffra clinical and real-world data at AASLD’s The Liver Meeting, Nov. 5-9, 2026, in Denver.
  • Real-world findings show improvements in liver health through 12 months among patients receiving the MASH treatment in routine clinical practice.
  • The RESONANCE program will contribute 13 abstracts; the largest real-world dataset covers more than 12,000 patients.
  • Clinical abstracts further characterize Rezdiffra’s positive effects on treatment-response measures, cardiovascular risk markers and patient-reported outcomes.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Madrigal Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610270800PRIMZONEFULLFEED9853398) on October 27, 2026, and is solely responsible for the information contained therein.